Compare TG Therapeutics Inc (TGTX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Utilities Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $54.88 (market cap $8.16B), while Utilities Select Sector SPDR Fund trades at $41.38 (market cap $23.60B). The key difference: Utilities Select Sector SPDR Fund is far larger — about 2.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| TGTX | XLU | |
|---|---|---|
Market Cap | $8.16B | $23.60B |
Volume | 1,735,121 | 28,758,237 |
Sector | Health | — |
52-Week High | $59.06 | $47.73 |
52-Week Low | $26.94 | $39.25 |
Typical Hold Time | 16 Days | 80 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
XLU trades at $41.35, up 0.49% with a mixed technical signal showing bullish moving averages but neutral oscillators. The ETF recently hit 52-week lows amid utility sector pressure from rising interest rates. Support levels cluster around $40-41 with resistance at $42. Recent news highlights oversold conditions and defensive positioning opportunities.
The outlook remains cautious with interest rate sensitivity being the primary risk. Defensive characteristics may appeal during market volatility, but sector headwinds from AI power demand shifts and regulatory challenges require monitoring. Current technical positioning suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
